220093-41-4

Basic information

• Product Name: 2-Azabicyclo[2.2.1]heptane-3-carboxylicacid,methylester,(1R,3S,4S)-rel-(9CI)
• Synonyms: 2-Azabicyclo[2.2.1]heptane-3-carboxylicacid,methylester,(1R,3S,4S)-rel-(9CI)
• CAS NO: 220093-41-4
• Molecular Formula: C8H13NO2
• Molecular Weight: 155.19432
• Product Categories: GLYCINESCAFFOLD;CARBOXYLICESTER;PYRROLE
• Mol File: 220093-41-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Azabicyclo[2.2.1]heptane-3-carboxylicacid,methylester,(1R,3S,4S)-rel-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Azabicyclo[2.2.1]heptane-3-carboxylicacid,methylester,(1R,3S,4S)-rel-(9CI)(220093-41-4)
• EPA Substance Registry System: 2-Azabicyclo[2.2.1]heptane-3-carboxylicacid,methylester,(1R,3S,4S)-rel-(9CI)(220093-41-4)

Safety Data

• Hazardous Substances Data: 220093-41-4(Hazardous Substances Data)

Usage

Properties

1. Chemical compound with a complex molecular structure
2. Form of the amino acid proline
3. Used in organic synthesis and pharmaceutical research
4. Chiral building block in the synthesis of pharmaceuticals and biological compounds

Specific content

1. Name: 2-Azabicyclo[2.2.1]heptane-3-carboxylic acid, methyl ester, (1R,3S,4S)-rel-(9CI)
2. Molecular structure: Complex and chiral
3. Usage: Organic synthesis and pharmaceutical research
4. Role: Valuable tool for creating complex chemical compounds and studying biological processes

Upstream product

• 134795-25-8 (1R,3R,4S)-N-tert-butoxycarbonyl-2-azabicyclo[2.2.1]heptane-3-carboxylic acid 
• 542-92-7 cyclopenta-1,3-diene 
• 130195-74-3 (1R,3R,4S)-2-[(1S)-1-phenylethyl]-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylic acid methyl ester 
• 130194-96-6 (1S,3S,4R)-2-[(1R)-1-phenylethyl]-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylic acid methyl ester 
• 141232-74-8 rac-(1S,3S,4R)methyl 2-benzyl-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylate 
• 141232-74-8 methyl (2-benzyl-2-azabicyclo[2.2.1]hept-5-ene)-3-carboxylate 
• 99940-87-1 2-carbobenzyloxy-3-carbomethoxy-2-azabicyclo<2.2.1>hept-5-ene 

Downstream Products

• 1256383-55-7 methyl ((S)-1-((1R,3S,4S)-3-(5-(4-bromophenyl)-1H-imidazol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1256387-76-4 (1R,3S,4S)-tert-butyl 3-(6-(4'-(2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1Himidazol-5-yl)biphenyl-4-yl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1256387-73-1 3-(2-amino-4-bromo-phenylcarbamoyl)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 134795-25-8 (1R,3S,4S)-2-aza-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2-tert-butyl ester 
• 1256383-53-5 (1R,3S,4S)-tert-butyl 3-(5-(4-bromophenyl)-1H-imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1256383-56-8 methyl ((S)-3-methyl-1-oxo-1-((1R,3S,4S)-3-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)butan-2-yl)carbamate 
• 1256383-58-0 methyl (S)-1-((S)-2-(5-(4'-(2-((1R,3S,4S)-2-((S)-2-(acetoxyamino)-3-methylbutanoyl)-2-azabicyclo[2.2.1]heptan-3-yl)-1H-imidazol-5-yl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate 
• 1256387-74-2 (1R,3S,4S)-3-(6-bromo-1H-benzimidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester 
• 1256387-75-3 (1R,3S,4S)-tert-butyl 3-(6-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1256387-78-6 methyl (S)-1-((S)-2-(5-(4'-(2-((1R,3S,4S)-2-((S)-2-(acetoxyamino)-3-methylbutanoyl)-2-azabicyclo[2.2.1]heptan-3-yl)-1H-benzo[d]imidazol-6-yl)biphenyl-4-yl)-1Himidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate 
• 1256387-87-7 (1R,3S,4S)-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester 
• 1256388-51-8 methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]-hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate 
• 1181573-36-3 (1R,3S,4S)-2-azabicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2-tert-butyl ester 3-methyl ester 
• 134795-25-8 (1R,3R,4S)-N-tert-butoxycarbonyl-2-azabicyclo[2.2.1]heptane-3-carboxylic acid 

Relevant articles and documents

MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES

The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl -mediated disorders.

Method for reducing content of diastereoisomer impurity in Ledipasvir intermediate

The invention discloses a method for reducing content of a diastereoisomer impurity (Ia) in a Ledipasvir intermediate (1R,3S,4S)-N-t-butyloxycarboryl-2-azabicyalo[2.2.1]heptane-3-carboxylic acid (I). The method comprises the steps of firstly taking a crude product of a compound shown as a formula (I) and containing the diastereoisomer impurity (Ia), dissolving in an organic solvent, adding alkaline organic amine to react with the crude product, separating out a solid, and filtering to obtain an amine salt of the compound shown as the formula (I); acidizing the obtained amine salt in an aqueous phase solution; extracting an obtained aqueous phase, separating out a solid, and separating to obtain the high-purity Ledipasvir intermediate (I). The product obtained by the method has a de value up to more than 99.5 percent, and the yield of more than 80 percent; reaction conditions in the method are mild, raw materials are easy to get, and the method is suitable for industrial application.

Preparation method of high-purity Ledipasvir intermediate

The invention discloses a preparation method of a high-purity Ledipasvir intermediate (1R, 3S and 4S)-N-t-butylcarbonyl-2-azabicyalo[2.2.1] heptane-3-carboxylic acid. According to the method, (1R, 3S and 4S)-N-t-butylcarbonyl-2-azabicyalo[2.2.1] heptane-3-carboxylate serves as an initial raw material, and the Ledipasvir intermediate is obtained through enzymatic hydrolysis. A test proves that the high-purity Ledipasvir intermediate is obtained and a feasible path is provided for reducing production cost and improving drug use safety. Meanwhile, the method has the advantages that operation is easy, environment friendliness is achieved, the yield is high, selectivity is high and cost is low; large-scale production can be achieved, and industrial application and popularization are facilitated.

Discovery of ledipasvir (GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection

A new class of highly potent NS5A inhibitors with an unsymmetric benzimidazole-difluorofluorene-imidazole core and distal [2.2.1]azabicyclic ring system was discovered. Optimization of antiviral potency and pharmacokinetics led to the identification of 39 (ledipasvir, GS-5885). Compound 39 (GT1a replicon EC50 = 31 pM) has an extended plasma half-life of 37-45 h in healthy volunteers and produces a rapid >3 log viral load reduction in monotherapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients. 39 has been shown to be safe and efficacious, with SVR12 rates up to 100% when used in combination with direct-acting antivirals having complementary mechanisms.

A rigid dirhodium(II) carboxylate as an efficient catalyst for the asymmetric cyclopropanation of olefins

The dirhodium(II) complex 7 of (1S,3R,4R)-2-(p-tert-butylphenylsulphonyl)-2-aza-bicyclo[2.2.1]heptane-3- carboxylic acid (3) (or its enantiomer) was synthesised in four steps from cyclopentadiene, (R)- or (S)-phenylethylamine and methyl glyoxylate. Comple

Highly diastereoselective reaction of 2-azanorbornyl enolates with electrophiles

(matrix presented). A highly diastereoselective reaction of 2-azanorbornyl enolates with electrophiles has been studied. Deprotonation of 4 with LDA at low temperature affords the corresponding exocyclic lithium enolate 5, which reacts with different elec

Synthesis of potential thromboxane A2 antagonists based on the aza-bicycloheptane skeleton

Thirteen compounds having a 2-aza or a 7-aza bicycloheptane framework substituted on carbon-3 by a prostanoic chain have been synthesized starting from easily obtained hetero-Diels Alder adducts. Due to their structure, a TxA2 antagonist

2-Azabicycloheptane-3-carboxylic Acid - A Bicyclic Proline

Diels-Alder reaction of cyclopentadiene and methyl N-carbobenzyloxy-2-iminoacetate generated in situ from methyl 2-chloro-N-carbobenzyloxyglycinate by triethylamine gave the N-carbobenzyloxy unsaturated bicyclic proline ester.This was converted in two ste